# A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

> **NCT03597282** · PHASE1 · TERMINATED · sponsor: **BioNTech US Inc.** · enrollment: 22 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** NEO-PV-01
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Adjuvant
- **BIOLOGICAL:** APX005M
- **BIOLOGICAL:** ipilimumab

## Key facts

- **NCT ID:** NCT03597282
- **Lead sponsor:** BioNTech US Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-08
- **Primary completion:** 2020-05-05
- **Final completion:** 2020-08-11
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Closed due to historically slow enrollment compounded by the COVID-19 pandemic.
- **Last updated:** 2020-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03597282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03597282, "A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03597282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*